TY - JOUR
T1 - Hepatitis-associated aplastic anaemia
T2 - epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party
AU - Locasciulli, Anna
AU - Bacigalupo, Andrea
AU - Bruno, Barbara
AU - Montante, Barbara
AU - Marsh, Judith
AU - Tichelli, Andre
AU - Socie, Gerard
AU - Passweg, Jakob
AU - Severe Aplastic Anemia Working
PY - 2010/6
Y1 - 2010/6
N2 - In order to assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first-line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non-HAA patients, HAA patients were younger (15 vs. 20 years, P <0 center dot 001), with a male prevalence (68% vs. 58%P = 0 center dot 002), and were treated earlier after diagnosis (46 vs. 62 d; P <0 center dot 001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first-line immunosuppression was 69%, and did not differ according to aetiology. The 10-year actuarial survival after transplantation was 70%, and was comparable in HAA and non-HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
AB - In order to assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first-line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non-HAA patients, HAA patients were younger (15 vs. 20 years, P <0 center dot 001), with a male prevalence (68% vs. 58%P = 0 center dot 002), and were treated earlier after diagnosis (46 vs. 62 d; P <0 center dot 001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first-line immunosuppression was 69%, and did not differ according to aetiology. The 10-year actuarial survival after transplantation was 70%, and was comparable in HAA and non-HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
KW - hepatitis-associated aplastic anaemia
KW - immunosuppression
KW - bone marrow transplantation
KW - MARROW TRANSPLANTATION
KW - BONE-MARROW
KW - VIRUS
U2 - 10.1111/j.1365-2141.2010.08194.x
DO - 10.1111/j.1365-2141.2010.08194.x
M3 - Article
SN - 0007-1048
VL - 149
SP - 890
EP - 895
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 6
ER -
